Consortia-based Analytical Validation of Assays for Drug Development

Time: 3:45 pm
day: Day One


• Defining a biomarker context of use and building evidentiary criteria to support its final use as a drug development tool
• Challenges and opportunities of blood-based measures for clinical trial enrichment strategies in CNS
• Leveraging cross-stakeholder engagement to design and implement a pre-competitive collaboration for familial f-FTD and allied disease areas (f-ALS, HD, and early-onset AD)